Targeting of the immune system in systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is a complex immune disorder in which loss of tolerance to nucleic acid antigens and other crossreactive antigens is associated with the development of pathogenic autoantibodies that damage target organs, including the skin, joints, brain and kidney. New drugs based on modulation of the immune system are currently being developed for the treatment of SLE. Many of these new therapies do not globally suppress the immune system but target specific activation pathways relevant to SLE pathogenesis. Immune modulation in SLE is complicated by differences in the immune defects between patients and at different disease stages. Since both deficiency and hyperactivity of the immune system can give rise to SLE, the ultimate goal for SLE therapy is to restore homeostasis without affecting protective immune responses to pathogens. Here we review recent immunological advances that have enhanced our understanding of SLE pathogenesis and discuss how they may lead to the development of new treatment regimens.
Ramanujam
Meera
M
Feinstein Institute for Medical Research, NS-LIJHS, Manhasset, NY 11030, USA.
Davidson
Anne
A
D000818:Animals; D016207:Cytokines / Q000276:immunology / Q000502:physiology; D016503:Drug Delivery Systems; D006801:Humans; D007107:Immune System / Q000187:drug effects* / Q000473:pathology; D007113:Immunity, Innate / Q000276:immunology; D007167:Immunotherapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008181:Lupus Nephritis / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation / Q000276:immunology; D008954:Models, Biological
D016207:Cytokines